People In Brief
This article was originally published in The Tan Sheet
Executive Summary
FDA appoints global, IT heads: The agency has chosen Lou Valdez as associate commissioner for international programs and Lori Davis as chief information officer. Valdez will lead the agency's further international expansion, with office openings planned for India, Latin America and the Middle East, FDA says Jan. 12. Melinda Plaisier stepped down as associate commissioner for international programs in October to become director of the Central region office in FDA's Office of Regulatory Affairs (1"The Tan Sheet" Dec. 8, 2008, p. 8). Davis has been deputy CIO since November 2007 and will now drive FDA's multi-year information technology modernization program, which will improve import and food protection by enhancing system interoperability
You may also be interested in...
HBW US Market News: Awards, Appointments, Actions And Nutrition And Disaster Relief
Kochanowski retires with CHPA Career Achievement award; Haelon’s Paley chairs CHPA board; House Oversight Committee chair, FTC commissioner speak at NCPA Fly-In; NasoClenz provided to help consumers following East Palestine disaster; CRN’s Mister attends White House End Hunger launch.
Opening China Offices Brings FDA Early Test On Bridging Globalization Gaps
FDA's opening of offices in China will be an early test of how the agency handles the challenges of globalization, not only in working with foreign governments but also in restructuring itself to operate with worldwide footing
Sales & Earnings In Brief
Schering-Plough looks to emerging markets: As the U.S. economy continues to falter, Schering-Plough is increasingly focusing on emerging markets such as Brazil, China and Russia, CEO Fred Hassan says in an Oct. 21 third-quarter earnings release. He notes 70 percent of S-P's $4.6 billion in third-quarter net sales were outside the U.S. He adds, consumer and animal health account for approximately $758 million and $278 million of sales respectively. Laxative Miralax drove a 2 percent increase in OTC revenues with $31 million in sales - nearly double last year's third-quarter total. This was not enough to offset weak allergy sales with Claritin down 11 percent to $92 million. Other OTC sales slipped 11 percent to $37 million, contributing to a 1 percent fall of overall OTC sales to $160 million. Beyond OTCs, Kenilworth, N.J.-based S-P's net income fell 21 percent to $589 million in the third quarter